cgib.ca

News

  • The Trillium Drug Program, part 4: What advisors need to do

    What can advisors tell their clients to minimize the impact of drug costs on their plans? In terms of plan design, Tim Spark, president of RTM Benefit Partners in Toronto, suggests employers implement 10% to 20% co-insurance.

    Read More
  • The Trillium Drug Program, part 3: Coping with catastrophic drug claims

    Some 275 advisors and other industry experts attended a Canadian Group Insurance Brokers (CGIB) seminar in May focusing on the role of Ontario’s Trillium Drug Program in the context of new high-cost drugs, such as those used to treat auto-immune disease or hepatitis C. Many in the audience were small business advisors whose clients have […]

    Read More
  • The Trillium Drug Program, part 2: Avoiding quick fixes

    In the second part of a four-part series, Patti Ryan looks at how strategies that lead to short-term gain cause long-term pain — and how this reality needs to be communicated. In part one, she examined small businesses’ inability to make the Trillium Drug Program    

    Read More
  • The Trillium Drug Program, part 1: What’s happening now

    Many advisors say it’s a real head-scratcher how this has gone on so long, but it has: Millions of dollars in catastrophic drug claims over the years have been paid for through small businesses’ insurance plans when they should have been funded by Ontario’s Trillium Drug Program.    

    Read More
  • Insurers error driving costs up

    Ontario’s Trillium Drug Program (TDP) could go a long way to reducing some of the strain drug costs are placing on plan sponsors. Too bad insurers aren’t using it correctly.    

    Read More
  • Downward Pressure On Drug Prices Over

    The downward pressure which was keeping drug plan costs from increasing is probably over, says Barb Martinez, of Great West Life. In the session ‘A peek into the future of drug spending’ at the Canadian Group Insurance Brokers seminar, she said there were several factors which were keeping drug costs.    

    Read More
  • What has your MGA done for you lately? Pt. 2 – October 1 CGIB seminar

    In the second of a two-part series, Patti Ryan debunks the myths surrounding MGAs. A recent Canadian Group Insurance Brokers (CGIB) seminar focused on group MGAs. Part of the discussion was devoted to unravelling some of the myths that have grown up around the notion of MGAs. The seminar covered eight myths, but three of […]

    Read More
  • What has your MGA done for you lately? Pt. 1 – October 1 CGIB seminar

    In the first of two parts, Patti Ryan look at the benefits of working with an managing general agency. In the world of group insurance, misconceptions about managing general agencies (MGAs) abound. What’s myth and what’s fact?    

    Read More
  • Patient choice cards: The good, the bad and the bottom line, part 2 – Small Biz Advisor

    What’s in a patient choice card, and should you recommend them to clients? Patient choice cards are issued by pharmaceutical firms and made available to patients by providers such as RxHelp or STI Technologies, or sometimes by physicians or pharmacies directly. Patients present them when filling prescriptions for brand name medications.    

    Read More
  • Patient choice cards: The good, the bad and the bottom line, part 1 – Small Biz Advisor

    What’s in a patient choice card, and should you recommend them to clients? Patient choice cards are issued by pharmaceutical firms and made available to patients by providers such as RxHelp or STI Technologies, or sometimes by physicians or pharmacies directly. Patients present them when filling prescriptions for brand name medications.    

    Read More